Loading...
Kubota Pharmaceutical Holdings Co., Ltd.
4596.T•JPX
Healthcare
Biotechnology
¥49.00
¥0.00(0.00%)
Kubota Pharmaceutical Holdings Co., Ltd. (4596.T) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Kubota Pharmaceutical Holdings Co., Ltd. (4596.T), covering cash flow, earnings, and balance sheets.
Revenue Growth
-31.83%
↓ 31.83%
Operating Income Growth
7.52%
↑ 7.52%
Net Income Growth
10.52%
↑ 10.52%
Operating Cash Flow Growth
10.48%
↑ 10.48%
Operating Margin
-3834.73%
↓ 3834.73%
Gross Margin
-1766.67%
↓ 1766.67%
Net Profit Margin
-4247.52%
↓ 4247.52%
ROE
-78.96%
↓ 78.96%
ROIC
-91.93%
↓ 91.93%
Kubota Pharmaceutical Holdings Co., Ltd. (4596.T) Income Statement & Financial Overview
View the income breakdown for Kubota Pharmaceutical Holdings Co., Ltd. 4596.T across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $10.03M | $7.37M | $4.75M | $5.04M |
| Cost of Revenue | $545.09M | $1.80M | $1.06M | $1.04M |
| Gross Profit | -$535.06M | $5.57M | $3.69M | $3.99M |
| Gross Profit Ratio | -$53.35 | $0.76 | $0.78 | $0.79 |
| R&D Expenses | $124.80M | $113.97M | $140.39M | $164.67M |
| SG&A Expenses | $161.08M | $171.62M | $201.08M | $176.74M |
| Operating Expenses | -$201.58M | $285.59M | $324.36M | $341.41M |
| Total Costs & Expenses | $343.51M | $287.40M | $342.53M | $342.45M |
| Interest Income | $0.00 | $0.00 | $1.99M | $2.40M |
| Interest Expense | $0.00 | $0.00 | $2.001M | $2.08M |
| Depreciation & Amortization | $17.32M | $16.60M | $17.11M | $14.61M |
| EBITDA | -$316.15M | -$263.42M | -$307.08M | -$326.05M |
| EBITDA Ratio | -$31.52 | -$35.72 | -$64.66 | -$64.74 |
| Operating Income | -$333.48M | -$280.02M | -$337.78M | -$337.41M |
| Operating Income Ratio | -$33.25 | -$37.97 | -$71.13 | -$67.000 |
| Other Income/Expenses (Net) | $314000.00 | -$50.73M | $11.59M | -$5.33M |
| Income Before Tax | -$333.16M | -$330.75M | -$326.19M | -$342.74M |
| Income Before Tax Ratio | -$33.22 | -$44.85 | -$68.69 | -$68.06 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$3.25M |
| Net Income | -$333.16M | -$330.75M | -$326.19M | -$342.74M |
| Net Income Ratio | -$33.22 | -$44.85 | -$68.69 | -$68.06 |
| EPS | -$5.89 | -$5.87 | -$5.79 | -$6.10 |
| Diluted EPS | -$5.89 | -$5.87 | -$5.79 | -$6.10 |
| Weighted Avg Shares Outstanding | $56.55M | $56.38M | $56.34M | $56.16M |
| Weighted Avg Shares Outstanding (Diluted) | $56.55M | $56.38M | $56.30M | $56.16M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan